Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses.

MLA

Olszewski, Adam, et al. “Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses.” Clinical Lymphoma, Myeloma & Leukemia, vol. 21, Sept. 2021, p. S239. EBSCOhost, https://doi.org/10.1016/S2152-2650(21)01501-9.

APA

Olszewski, A., Avigdor, A., Babu, S., Levi, I., Eradat, H., Abadi, U., Holmes, H., McKinney, M., Woszczyk, D., Giannopoulos, K., Jurczak, W., McCord, R., Yuying Xie, Mingzhu Zhou, Qayum, N., O’Hear, C., Sellam, G., & Horowitz, N. (2021). Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses. Clinical Lymphoma, Myeloma & Leukemia, 21, S239. https://doi.org/10.1016/S2152-2650(21)01501-9

Chicago

Olszewski, Adam, Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat, Uri Abadi, Houston Holmes, et al. 2021. “Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses.” Clinical Lymphoma, Myeloma & Leukemia 21 (September): S239. doi:10.1016/S2152-2650(21)01501-9.